

NERVGEN PHARMA CORP.

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Expressed in Canadian dollars)

(Unaudited)

	For the 3 Months Ended September 30, 2019 \$	For the 3 Months Ended September 30, 2018 \$	For the 9 Months Ended September 30, 2019 \$	For the 9 Months Ended September 30, 2018 \$
Operating expenses				
Research and development (Note 12)	1,656,737	285,240	4,656,509	293,203
General and administration (Note 12)	708,778	230,301	2,302,015	297,312
Total operating expenses	2,365,515	515,541	6,958,524	590,515
Interest income	(34,214)	-	(80,626)	-
Net loss and comprehensive loss for the period	(2,331,301)	(515,541)	(6,877,898)	(590,515)
Basic and diluted net loss per share	(0.08)	(0.04)	(0.28)	(0.12)
Weighted average common shares outstanding (Note 9)	27,851,659	12,820,118	24,965,212	4,986,942

The accompanying notes are an integral part of these condensed consolidated interim financial statements